Oddifact
AI platform that prepares orphan drug programs for rare diseases and hands them to pharma partners for development
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-02
About Oddifact
Oddifact is an AI-driven biotechnology company focused on new treatments for rare diseases. Its platform analyzes existing molecules and scientific evidence to identify high-potential indications, then converts them into structured, evidence-backed program packages for the FDA Orphan Drug Designation pathway.
Its pipeline is biologics-first. Pharmaceutical partners take the programs forward into clinical development, regulatory approval and commercialization. The company activates underused academic and biomedical research as a source of candidates.
Oddifact was founded in 2024 and is headquartered in Paris. It reports 11 Orphan Drug Designations granted and 16 FDA Orphan Drug Designation submissions. It has announced a collaboration with Mabion S.A. that received an FDA Pre-IND meeting grant for RTX-NP in immune thrombocytopenia.
Product: AI platform that analyzes molecules and scientific evidence to identify rare disease indications and build Orphan Drug Designation program packages.
Jobs at Oddifact
Leadership
- Mehdi-Alexandre Manga · Co-Founder & Chief Innovation OfficerSource: company website
- Pierre-Alexandre Teulié · Co-Founder & CEOSource: company website
More biotech & pharma companies
OGD2 Pharma
Biotherapy developer targeting the tumour-restricted OAcGD2 antigen for high-risk neuroblastoma treatmentNew on EvolcOncodesign Services
Preclinical CRO running in vivo pharmacology, imaging and radiopharmaceutical studies for biotech and pharma sponsorsNew on EvolcRemote-friendlyOne Biosciences
Single-cell tumour profiling from biopsy samples for oncologists and pharma and biotech drug developersNew on EvolcOrakl Oncology
Oncology drug discovery and clinical-response prediction for biopharma companies and research hospitalsYoung companyNew on EvolcOrganotechnie
Manufactures peptones, protein hydrolysates and magnesium pidolate for pharmaceutical, biotechnology and industrial fermentation customersNew on EvolcOsivax
Develops universal vaccines for influenza and other infectious diseases using an oligoDOM nanoparticle platformNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.